Pronunciation(s): vye-TECK-ta; el-vye-TEG-ra-veer
|What is Vitekta?
- Vitekta is an integrase inhibitor by Gilead Sciences. It was approved as a stand-along drug in September 2014, for use in combination with Norvir (ritonavir) and other HIV medications. It is also a component of the fixed-dose combination tablet Stribild (elvitegravir plus cobicistat plus tenofovir plus emtricitabine).
- After HIV's genetic material is deposited inside a cell, its RNA must be converted (reverse transcribed) into DNA. A viral enzyme called integrase then helps to hide HIV's DNA inside the cell's DNA. Once this happens, the cell can begin producing genetic material for new viruses. Integrase inhibitors, such as elvitegravir, are designed to block the activity of the integrase enzyme and to prevent HIV DNA from entering healthy cell DNA.
- Vitekta will need to be used in combination with other drugs, including Norvir.
What is already known about Vitekta?
- Vitekta is available in two doses: an 85 mg tablet and a 150 mg tablet. The dose will depend on other drugs selected to be combined with Vitekta. For example, if it is combined with twice-daily Kaletra (lopinavir/ritonavir) or once-daily Norvir and Reyataz, the 85 mg tablet should be used once daily. If Vitekta is combined with twice-daily Norvir and twice-daily Lexiva (fosamprenavir), Prezista (darunavir), or Aptivus (tipranavir), the 150 mg tablet should be used once daily.
- Vitekta, especially when combined with either Norvir or GIlead's boosting agent Tybost (cobicistat), might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
What is known about side effects?
- According to clinical trial results, the most common side effects associated with therapy that includes Vitekta include nausea, diarrhea, and headache.
Who should not take Vitekta?
- It is not known whether Vitekta will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
- It is not known whether Vitekta passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.
Where can I learn more about clinical trials of Vitekta?
- If you would like to find out if you are eligible for any clinical trials that include Vitekta visit ClinicalTrials.gov, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email firstname.lastname@example.org.